These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10789338)

  • 41. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
    Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
    PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
    Weiss EM; Bilder RM; Fleischhacker WW
    Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of antipsychotics on mortality in schizophrenia: systematic review.
    Weinmann S; Read J; Aderhold V
    Schizophr Res; 2009 Aug; 113(1):1-11. PubMed ID: 19524406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term phase of schizophrenia: impact of atypical agents.
    Naber D
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S11-4. PubMed ID: 11252518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
    Meltzer HY; Thompson PA; Lee MA; Ranjan R
    Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):27S-33S. PubMed ID: 8866741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipsychotics and the quality of life of schizophrenic patients.
    Loga-Zec S; Loga S
    Psychiatr Danub; 2010 Dec; 22(4):495-7. PubMed ID: 21169888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atypical antipsychotic agents: a critical review.
    Worrel JA; Marken PA; Beckman SE; Ruehter VL
    Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotics and amotivation.
    Fervaha G; Takeuchi H; Lee J; Foussias G; Fletcher PJ; Agid O; Remington G
    Neuropsychopharmacology; 2015 May; 40(6):1539-48. PubMed ID: 25567425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life measurement during antipsychotic drug therapy of schizophrenia.
    Voruganti LN; Heslegrave RJ; Awad AG
    J Psychiatry Neurosci; 1997 Jul; 22(4):267-74. PubMed ID: 9262049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subjective well-being and quality of life under atypical antipsychotic treatment.
    Karow A; Naber D
    Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of novel antipsychotic drugs on quality of life among people suffering from schizophrenia.
    Jukić V; Barić V; Culav-Sumić J; Herceg M; Majdancić Z; Werft-Cop M
    Coll Antropol; 2003; 27 Suppl 1():119-24. PubMed ID: 12955901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study.
    Guo X; Zhang Z; Zhai J; Fang M; Hu M; Wu R; Liu Z; Zhao J;
    Compr Psychiatry; 2012 Oct; 53(7):1006-12. PubMed ID: 22516246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
    Davies LM; Lewis S; Jones PB; Barnes TR; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
    Br J Psychiatry; 2007 Jul; 191():14-22. PubMed ID: 17602120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.